Immunotherapy of Neuroblastoma Targeting GD2 and Beyond

Jung Tung Hung; Alice L. Yu

doi:10.1007/978-981-19-7732-9_10

Immunotherapy of Neuroblastoma Targeting GD2 and Beyond

Jung Tung Hung
, Alice L. Yu^*

^*Corresponding author for this work

Chang Gung Memorial Hospital
University of California at San Diego

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk neuroblastoma, which comprises ~50% of neuroblastoma, is dismal. Abundant expression of disialoganglioside GD2 antigens is a feature of neuroblastoma. The success of immunotherapy targeting the GD2 antigen with dinutuximab has fueled the interest in developing improved immunotherapeutics including humanized anti-GD2 antibodies, GD2 mimotopes, cytokine-fused GD2-specific antibodies, GD2-specific chimeric antigen receptor T/NKT cells, GD2 vaccine, anti-GD2 idiotype monoclonal antibody, and anti-O-acetyl GD2 antibody. Advance in these active or passive cancer immunotherapies hold promises to further improve the outcome of neuroblastoma.

Original language	English
Title of host publication	Glycosignals in Cancer
Subtitle of host publication	Molecular Assembly and Recognition, Second Edition
Publisher	Springer Nature
Pages	215-238
Number of pages	24
ISBN (Electronic)	9789811977329
ISBN (Print)	9789811977312
DOIs	https://doi.org/10.1007/978-981-19-7732-9_10
State	Published - 01 01 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© Springer Nature Singapore Pte Ltd. 2016, 2023.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

14G2a
CAR T
Cancer immunotherapy
GD2
Neuroblastoma
ch14.18

Access to Document

10.1007/978-981-19-7732-9_10

Cite this

@inbook{3b9d1d68d64b43ed933da8bcd40c8b56,

title = "Immunotherapy of Neuroblastoma Targeting GD2 and Beyond",

abstract = "Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk neuroblastoma, which comprises \textasciitilde{}50\% of neuroblastoma, is dismal. Abundant expression of disialoganglioside GD2 antigens is a feature of neuroblastoma. The success of immunotherapy targeting the GD2 antigen with dinutuximab has fueled the interest in developing improved immunotherapeutics including humanized anti-GD2 antibodies, GD2 mimotopes, cytokine-fused GD2-specific antibodies, GD2-specific chimeric antigen receptor T/NKT cells, GD2 vaccine, anti-GD2 idiotype monoclonal antibody, and anti-O-acetyl GD2 antibody. Advance in these active or passive cancer immunotherapies hold promises to further improve the outcome of neuroblastoma.",

keywords = "14G2a, CAR T, Cancer immunotherapy, GD2, Neuroblastoma, ch14.18",

author = "Hung, \{Jung Tung\} and Yu, \{Alice L.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2016, 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-981-19-7732-9\_10",

language = "英语",

isbn = "9789811977312",

pages = "215--238",

booktitle = "Glycosignals in Cancer",

publisher = "Springer Nature",

}

TY - CHAP

T1 - Immunotherapy of Neuroblastoma Targeting GD2 and Beyond

AU - Hung, Jung Tung

AU - Yu, Alice L.

N1 - Publisher Copyright: © Springer Nature Singapore Pte Ltd. 2016, 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk neuroblastoma, which comprises ~50% of neuroblastoma, is dismal. Abundant expression of disialoganglioside GD2 antigens is a feature of neuroblastoma. The success of immunotherapy targeting the GD2 antigen with dinutuximab has fueled the interest in developing improved immunotherapeutics including humanized anti-GD2 antibodies, GD2 mimotopes, cytokine-fused GD2-specific antibodies, GD2-specific chimeric antigen receptor T/NKT cells, GD2 vaccine, anti-GD2 idiotype monoclonal antibody, and anti-O-acetyl GD2 antibody. Advance in these active or passive cancer immunotherapies hold promises to further improve the outcome of neuroblastoma.

AB - Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk neuroblastoma, which comprises ~50% of neuroblastoma, is dismal. Abundant expression of disialoganglioside GD2 antigens is a feature of neuroblastoma. The success of immunotherapy targeting the GD2 antigen with dinutuximab has fueled the interest in developing improved immunotherapeutics including humanized anti-GD2 antibodies, GD2 mimotopes, cytokine-fused GD2-specific antibodies, GD2-specific chimeric antigen receptor T/NKT cells, GD2 vaccine, anti-GD2 idiotype monoclonal antibody, and anti-O-acetyl GD2 antibody. Advance in these active or passive cancer immunotherapies hold promises to further improve the outcome of neuroblastoma.

KW - 14G2a

KW - CAR T

KW - Cancer immunotherapy

KW - GD2

KW - Neuroblastoma

KW - ch14.18

UR - https://www.scopus.com/pages/publications/85172083256

U2 - 10.1007/978-981-19-7732-9_10

DO - 10.1007/978-981-19-7732-9_10

M3 - 章节

AN - SCOPUS:85172083256

SN - 9789811977312

SP - 215

EP - 238

BT - Glycosignals in Cancer

PB - Springer Nature

ER -

Immunotherapy of Neuroblastoma Targeting GD2 and Beyond

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this